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A B S T R A C T
Transcribing RNA polymerase II (RNAPII) is decorated by a plethora of post-translational modifications that
mark different stages of transcription. One important modification is RNAPII ubiquitylation, which occurs in
response to numerous different stimuli that cause RNAPII stalling, such as DNA damaging agents, RNAPII in-
hibitors, or depletion of the nucleotide pool. Stalled RNAPII triggers a so-called “last resort pathway”, which
involves RNAPII poly-ubiquitylation and proteasome-mediated degradation. Different approaches have been
described to study RNAPII poly-ubiquitylation and degradation, each method with its own advantages and ca-
veats. Here, we describe optimised strategies for detecting ubiquitylated RNAPII and studying its degradation,
but these protocols are suitable for studying other ubiquitylated proteins as well.
1. Introduction
Transcription by RNA Polymerase II (RNAPII) is not a continuous
process but rather involves frequent pausing, stalling or irreversible
arrest, here collectively referred to as transcription stress. A number of
elongation-stimulating factors have evolved to help RNAPII overcome
these transcription-impeding events, yet resumption of transcription
may not always be possible [1,2]. Indeed, on its way along the gene,
RNAPII faces obstacles, such as DNA damage, DNA-bound proteins, or
DNA sequences that are intrinsically difficult to transcribe. Moreover,
when occurring in the transcribed strand, bulky DNA lesions caused by
genotoxic agents such as UV-irradiation, or chemicals such as cisplatin
or 4-nitroquinoline 1-oxide (4-NQO) will completely block RNAPII
progression [3,4]. Transcription stress can also be induced in-
dependently of DNA damage, for example through depletion of the
nucleotide pool by treatment with 6-azauracil (6-AU) in the yeast
Saccharomyces cerevisiae [5], or through mutation of the gene encoding
elongation factor TFIIS, which causes prolonged RNAPII stalling [6].
The RNAPII elongation complex is remarkably stable, which is
crucial to ensure processivity of transcription under normal conditions.
However, this great stability comes at a cost: just a single stalled RNAPII
complex can block transcription of an entire gene. To avoid potentially
detrimental consequences of persistently stalled/arrested RNAPII, cells
have evolved several mechanisms to solve this problem. For example,
damage-stalled RNAPII can act as a DNA lesion sensor, triggering
transcription-coupled nucleotide excision repair (TC-NER) and removal
of the lesion, which would allow resumption of transcription [7,8].
However, RNAPII stalling/arrest, induced either by DNA damage or
other means, has also been shown to induce extensive RNAPII ubiqui-
tylation in vivo. Subsequently, poly-ubiquitylated RNAPII is subject to
proteasomal degradation [6,9–13].
Intriguingly, proteasome subunits have been found to associate with
several yeast genes, particularly gene ends, in a transcription-depen-
dent manner. Moreover, inhibition of proteasome proteolytic activity
resulted in transcription readthrough beyond the transcription termi-
nation site [14]. More recently, RNAPII degradation has been proposed
to play a role in hormone-induced enhancer decommissioning [15].
Additionally, some viruses have been shown to inhibit host cell tran-
scription via inducing RNAPII degradation [16,17], and RNAPII ubi-
quitylation can regulate splicing in yeast, in a manner independent of
proteasomal degradation [18]. These observations suggest that RNAPII
ubiquitylation and degradation may play roles beyond resolving ar-
rested RNAPII.
In the context of transcription arrest, experiments in yeast suggested
that RNAPII phosphorylated at serine 2 (S2) in the heptapeptide repeats
of the C-terminal domain (CTD) is subject to poly-ubiquitylation and
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degradation, while phosphorylation of CTD S5 inhibited RNAPII poly-
ubiquitylation in vitro [9]. This supports the idea that only elongating
RNAPII is targeted for ubiquitylation and degradation when it en-
counters a transcription-blocking event and stalls. An important ques-
tion that remains to be investigated is how the cells distinguish a stalled
RNAPII from normal elongating RNAPII.
RNAPII is composed of 12 subunits; however, only RPB1, the largest
and catalytic subunit, is subject to RNAPII arrest-induced degradation
in yeast [19]. RPB1 ubiquitylation is a complex, multistep process, with
multiple E3 ubiquitin ligases already having been implicated
[2,12,20–22]. Briefly, Rsp5 (NEDD4 in human cells) is responsible for
generating a K63 linked poly-ubiquitin chain on RPB1, which is then
trimmed to mono-ubiquitylation by the Rsp5-associated deubiquiti-
nating enzyme (DUB) Ubp2. In a reaction which is dependent on prior
mono-ubiquitylation, the Elongin complex finally produces a K48-
linked poly-ubiquitylation chain on RPB1 [12,13,20,23,24]. While this
two-ligase system has been successfully reconstituted for yeast and
mammalian factors in vitro [20], the human E3 ligase VHL has also been
shown to ubiquitylate RPB1 in vivo [25]. Moreover, depletion of specific
ligases in vivo results only in partial loss of ubiquitylation, or in lack of
RPB1 ubiquitylation only at specific stages of the response – for ex-
ample, depletion of NEDD4 abrogates RPB1 poly-ubiquitylation but
only at early timepoints after UV-irradiation in human cells [12]. To-
gether, these results suggest that two or more redundant pathways
leading to RNAPII poly-ubiquitylation and degradation may be active,
at least in human cells. Additionally, the yeast Def1 protein, which is
not an E3 ligase itself, facilitates Rpb1 degradation upon DNA damage
by enhancing recruitment of the Elongin complex to RNAPII [26]. Fi-
nally, Cdc48 (human p97), in complex with Ubx4/5, recognizes and
extracts poly-ubiquitylated Rpb1 from chromatin, in order for it to be
degraded by the proteasome [27,28]. To add to this complexity, the
DUB Ubp3 has been shown to digest poly-ubiquitin chains on yeast
Rpb1 [29], presumably to proofread and rescue Rpb1 from degradation.
Taken together, it is clear that although great progress has been made in
outlining the pathways and mechanisms responsible for RPB1 ubiqui-
tylation and degradation, it is possible that not all the key players in
this complex process have been identified. It thus remains to be clar-
ified or investigated which E3 ligases, DUBs and auxiliary factors are
involved in human RPB1 ubiquitylation/deubiquitylation, and how
their complex interplay is achieved.
In order to help address these questions, robust and reliable
methods to study ubiquitylation are required. Here, we discuss some of
these techniques and provide detailed protocols for tracking human and
yeast RPB1 ubiquitylation and degradation. We also briefly address
future perspectives, such as mapping individual ubiquitylation sites and
generating suitable cell model systems. Importantly, although the ap-
proaches described were designed specifically to investigate RNAPII
ubiquitylation, they can easily be modified to investigate ubiquitylation
of other proteins as well.
2. Inducing RNAP II ubiquitylation and degradation – reagents
and equipment
As mentioned above, many different kinds of stimuli can cause
ubiquitylation and degradation of RNAPII largest subunit, RPB1.
Among those cues, UV-irradiation is probably the best studied. Below,
we outline the equipment, protocols and considerations needed for UV-
irradiating human and yeast cells. We also provide a brief overview of
other protocols to trigger RPB1 ubiquitylation and degradation.
2.1. Equipment for UV-irradiation
Any device capable of emitting a regulated dose of UV light can
potentially be used to irradiate mammalian or yeast cells grown in
culture. UV light of any wavelength (UVA=315–400 nm,
UVB=280–315 nm, UVC=100–280 nm) can thus induce the
formation of DNA lesions (cyclobutane pyrimidine dimers (CPDs) and
(6-4)-photoproducts (6–4)PPs) [30]. When found in the transcribed
strand of active genes, CPDs and (4-6) PPs will cause RNAPII stalling
[3,4]. Here, we focus on UVC, as it is the most frequently used UV-
irradiation type in the literature.
The most commonly available irradiation devices are those routi-
nely used for crosslinking nucleic acids to membranes, for example UVC
crosslinkers (Fig. 1A). Although these crosslinking devices can often be
sufficient, there are important considerations to bear in mind. First,
these devices were designed primarily with the purpose of providing a
very high dose of UVC-irradiation, for the crosslinking of molecules to
membranes. As such, their reliability in the low UV-dose range required
for irradiation of live cells may not be optimal. Particularly, we noticed
that UV lamps/crosslinkers suffer from relatively high levels of incon-
sistency when providing the low doses of UVC (5–20 J/m2) typically
used to irradiate human cells, and that they give disconcertingly non-
uniform irradiation across the exposed surface (Fig. 1B). As an alter-
native to commercial UV crosslinkers, custom-made UV-irradiation
devices can be built, such as UV boxes with a longer, adjustable dis-
tance to the target material. Such boxes are particularly useful for ir-
radiating yeast cells, as they allow easy agitation/mixing of the sample
during irradiation so that uniform exposure of yeast cells to the UV
source is obtained.
A key component for all experimental settings is a UV meter (e.g.
VLX-3W). Whether using a UV-crosslinker or a UV box, the UV meter
probe can be inserted in the irradiation chamber to measure the actual
UV dose given. Due to the spatial variability in the actual given doses by
many UV sources, the experimental setup needs to be carefully tested
by measuring the UV dose across the surface of the irradiation device to
determine not only the uniformity of irradiation but also the maximum
size of the surface that can be accurately and uniformly irradiated (e.g.
see Fig. 1B).
Different UV-irradiation devices will achieve a given UV dose in
different amounts of time – for example, total emission of 20 J/m2
energy may take 2–3 s in a UV crosslinker, and∼10 s in a UV box with
greater distance between the UV lamp and the sample. In the context of
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Fig. 1. Equipment for UV irradiation of cells. (A) A typical UV crosslinker
(Stratalinker) device. (B) Variability of exposure across a typical UV crosslinker
(Stratalinker) surface. Desired doses were set to 20 J/m2 UVC and actual
emitted doses were measured with a UV meter at 9 different areas of the
crosslinker surface. The average of four measurements is indicated. The posi-
tions of the device’s light bulbs are indicated by arrows.
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RPB1 ubiquitylation and degradation, we are not aware of any differ-
ences in results whether cells receive a similar total dose over a shorter
or longer period of time.
2.2. Notes before starting
• Warm up the UV-irradiation device before use (10min for the UV
box, or give two pulses of 2500 J/m2 with crosslinkers).
• Make sure the expected doses are correct by using a UV-meter.
• The original media will need to be added back to the cells, therefore
it is important to carefully remove and store it for reuse.
2.3. UV-irradiation of human cells
At the time of irradiation, the cells should be around 60–80% con-
fluent and equally spread across the dish surface. Prior to irradiation it
is necessary to remove the culture medium entirely, and also to take the
lid of the dish off for irradiation (UVC rays do not pass through the
plastic). The experimenter should aim to work fast and avoid leaving
the cells without medium for more than a few minutes. The dishes
should be transferred from the tissue culture hood to the UV-irradiation
device with the dish lid kept on, to maintain sterility. The lid should be
taken off just before irradiation, inside the UV crosslinker chamber. The
lid should be kept facing down on a clean, sterilised surface. If the
samples will be used for assaying transcription, we recommend re-
plenishing each sample of cells with the medium they were grown in
before irradiation. Adding fresh medium can cause a “boost” in tran-
scription and potentially skew the results [31].
2.4. UV-irradiating yeast
Yeast cells should be in early log phase (5×106–2×107 cells/ml)
at the time of UV-irradiation. 25 μg/ml cycloheximide may be added
5min before starting the experiment (see below). The cells should be
washed and resuspended in PBS or saline for UV-irradiation. The ori-
ginal media should be saved as it will be re-added to the yeast cells after
treatment. We typically start with a 200ml culture per condition. The
culture is split in two, with one half irradiated and the other half saved
as the negative control. The cells are concentrated 5 times for the ir-
radiation such that 100ml of culture is resuspended in 20ml of PBS/
Saline, and irradiated in a pyrex dish with mixing of the sample during
irradiation, if possible. The UVC dose we give is usually 300 J/m2 (over
approximately 30 s), as measured with the UV meter. Immediately after
the samples have been irradiated they are collected by centrifugation
and resuspended in their original media for recovery. At this point, it is
important to keep the recovery cultures in a shaking incubator in the
absence of light, to ensure that activation of photolyase is prevented
[32]. Note: if possible, use YPD instead of minimal media to grow the
cells, as this tends to give more reproducible and robust results.
2.5. UV meter: the importance of monitoring the dose
Most UV-induced phenomena are dose dependent (see below).
Considering that some UV devices are inconsistent in providing a given
dose, it is of utmost importance to independently monitor the emitted
dose of irradiation with a UV radiation meter in every experiment.
While there are many UV radiation meters on the market, it is im-
portant for it to fulfil the following criteria:
• The meter should be able to measure the wavelength of the given
UV-irradiation device.
• The meter should be able to measure cumulative UV exposure (over
a period of time).
• The probe of the meter should have a cable of appropriate length to
be able to fit into the corresponding irradiation device’s chamber.
We have successfully used UV radiation meter VLX-3W with probe
SX254, with UVC crosslinkers and a UVC box.
2.6. Troubleshooting
Measuring low actual doses, or very variable actual doses between
samples. Potential causes:
• Device not warmed up properly. Warm up the device as re-
commended in “Notes before starting”, or try warming up for a
longer period of time.
• Old bulbs. Replace bulbs.
• If neither of the above helps, the device may not be suitable for
irradiation of live cells.
• For multi-well plates (24-well to 384-well) alternative irradiation
devices may need to be built to achieve consistent exposure across
samples. We have successfully constructed and used UV conveyor
belts that operate by having a single UVC light source in the centre
of the device’s chamber, and a moving conveyor belt that will carry
the sample through the chamber with constant speed [33].
2.7. Other stimuli that induce RPB1 degradation
Apart from UV-irradiation, other agents are also known to induce
RPB1 ubiquitylation and degradation. The common feature is that they
induce transcription stress either by creating transcription-blocking
DNA damage (e.g. UV, cisplatin, 4-NQO), by blocking RNAPII activity
(e.g. alpha-amanitin) or by depleting the NTP pool (e.g. 6-AU). The
commonly used dose ranges for these agents are listed in Table 1.
For practical reasons, it may be easier to use one of these chemicals
rather than UV-irradiation to induce RPB1 ubiquitylation and de-
gradation. For example, 4-NQO is typically used in yeast when per-
forming time-course experiments, as UV-irradiation of yeast requires a
significant amount of time to carry out, and might not be possible to
perform for multiple different strains or conditions in a time-course set-
up. We tested 4-NQO treatment in human cells and found that similarly
to yeast, it induces RPB1 poly-ubiquitylation and degradation, but at
much lower doses than those typically used for yeast (Fig. 2C). While all
of these agents will induce RPB1 ubiquitylation and degradation, it is
unclear if they do so via the exact same molecular mechanism (e.g.
using the same ubiquitin ligase pathways or the same ubiquitylation
sites on RPB1), although, to date, we have not observed any inherent
differences between them.
3. Detection of ubiquitylated RNAPII
3.1. Background
Mono-, oligo- or poly-ubiquitylation of proteins can often be de-
tected by simple Western blot analysis as additional, slower-migrating
bands and smears, for example for the well-known DNA damage-in-
duced mono-ubiquitylation of histone H2AX [34,35]. However, for
RPB1 this is not the case because i) RPB1 is a very large protein so it is
difficult to resolve and visualize these “extra” bands, ii) only a small
fraction of RPB1 molecules are ubiquitylated at any given time, even
Table 1
Agents that induce RPB1 poly-ubiquitylation and degradation, and the range of
doses used in the literature (recommended dose in brackets).
Reagent Dose (Human) Dose (yeast)
UVC-irradiation 2–100 J/m2 (typically 5–20 J/m2) Up to 300 J/m2
Cisplatin 5–50 μM for 1 h Not used
4-NQO 0.2–5 μM for 1 h 50 μM, 30min
6-AU Not tested 2mM, 2–3 h
Alpha amanitin 2–50 μM (10 μM) for 4 h Not used
A. Tufegdzic Vidakovic, et al. Methods 159–160 (2019) 146–156
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after high doses of UVC-irradiation.
In both mammalian and yeast cells, a faint band can sometimes be
seen above the phosphorylated RPB1 band in UV-irradiated samples
(for example Fig. 2B, overexposed Input lanes, 4H8), but it would be
challenging and likely unreliable to quantify this presumed ubiquity-
lation smear and compare between conditions. For these reasons, prior
enrichment of ubiquitylated RPB1 molecules is required. This can be
achieved by pulldown of all ubiquitylated proteins from the lysate and
then probing for RPB1 using specific antibodies in Western blot analysis
[12].
We note that other methods have been utilized where RPB1 is im-
munoprecipitated and then blotted with anti-ubiquitin antibodies.
However, these protocols may potentially detect not only ubiquitylated
RPB1 but also any other ubiquitylated proteins that co-im-
munoprecipitate with RPB1. Furthermore, other alternative procedures
sometimes enrich (hexahistidine- or epitope-) tagged ubiquitin and then
probe for RPB1. This approach is reliable, but sometimes impractical as
it requires the generation of cell lines which express tagged ubiquitin.
Below we describe the principles of the methods we regularly use to
easily and reliably detect ubiquitylation of RNAPII. Importantly, these
approaches can actually be used to detect any ubiquitylated protein for
which a specific antibody is available.
3.2. Method: enrichment of ubiquitylated proteins using Dsk2 or MultiDsk
pulldown
The budding yeast Dsk2 protein contains an UBA domain, which
binds ubiquitin with relatively high affinity [36]. This has been
exploited to generate GST-Dsk2 affinity resins that can enrich native,
ubiquitylated proteins from cell extracts (Fig. 2A) [12]. A further de-
velopment of this principle was TUBES [37], or MultiDsk resin [38],
which contain an array of four (TUBES), or five (MultiDsk) UBA do-
mains, respectively. We have worked extensively with MultiDsk and it
displays a dramatically higher affinity for ubiquitin and ubiquitin
chains than one Dsk2 domain alone, to the extent that ubiquitylated
proteins can effectively be depleted from the extract [38]. While Dsk2
protein appears to have some preference towards binding K48-linked
ubiquitin chains [36,39] and is therefore highly suitable for detecting
poly-ubiquitylated proteins destined for proteasomal degradation,
MultiDsk does not significantly discriminate between different types of
ubiquitin chains, and can also effectively detect mono-ubiquitylated
proteins [38]. We have used both Dsk2 and MultiDsk to successfully
enrich ubiquitylated RPB1 species [12,38].
Generation of GST-MultiDsk resin has already been described in
detail [38], and is slightly more challenging than generating GST-Dsk2
resin due to the relatively insoluble nature of the MultiDsk protein [38].
Below we provide a detailed protocol for the generation and use of GST-
Dsk2 affinity resin for enrichment of ubiquitylated RPB1, and also
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Fig. 2. Enrichment of ubiquitylated RNAPII species. (A) A sketch illustrating the principle of Dsk2 pulldown strategy (the same principles apply to MultiDsk). Dsk2
binds the ubiquitin moiety on proteins and this property is exploited to enrich ubiquitylated proteins from the extract. Note that, if used as indicated in text, this
method is capable of depleting the extract of ubiquitylated proteins. (B) Kinetics of RNAPII ubiquitylation upon UV irradiation in human cells. HEK293 TRex flpIn
cells were irradiated with 20 J/m2 UVC, and samples were taken at different timepoints after irradiation. Dsk2 analysis was performed as described in text. Note that
different exposures of the same Western blot membranes are shown. Approximate positions of the protein markers are indicated on the left. mUb, mono-ubiquitylated
RPB1. pUb, poly-ubiquitylated RPB1. “Ub?”, slower migrating RPB1 band, which may represent ubiquitylated species in the extract. (C) Analysis of RNAPII ubi-
quitylation upon 4-NQO treatment in HEK293 TRex flpIn cells. The cells were treated with the indicated doses of 4-NQO for 1 h, and Dsk2 analysis was performed as
described in the text.
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highlight the differences between this protocol and that used for gen-
eration of MultiDsk resin. MultiDsk is also available from several
commercial providers.
3.3. Preparation of GST-Dsk2 affinity resin
3.3.1. Reagents and equipment needed
• pGEX3-Dsk2 plasmid [12].
• One Shot BL21(DE3) or One Shot BL21(DE3) Star competent bac-
terial cells, and all the necessary equipment for bacterial transfor-
mation, growth and induction.
• PBSA buffer, protease inhibitors, Triton X-100, DTT.
• Glutathione sepharose beads, 50% packed bead volume solution.
• Sodium azide solution.
• 50ml falcon tubes, 200ml glass beakers.
• Tip probe sonicator (e.g. Branson Digital Sonifier 250).
• Centrifuge.
• For specific details of the reagents and equipment please refer to
Appendix.
3.3.2. Bacterial transformation, growth and lysate preparation:
• Day 1: Transform One Shot BL21(DE3) or One Shot BL21(DE3) Star
competent bacterial cells with pGEX3-Dsk2 plasmid according to the
manufacturer’s instructions, and plate cells on ampicillin selection
plates. Keep at 37 °C overnight.
• Day 2: pick a single colony and inoculate into 20ml of LB containing
100 μg/ml ampicillin (LBamp) and shake at 37 °C at 200 rpm over-
night. This is the pre-inoculum culture.
• Day 3:
o Inoculate 300ml of LBamp with 5ml of the pre-inoculum in 2L
Erlenmeyer flask. Shake at 37 °C at 200 rpm.
o Regularly take 1ml aliquots to track bacterial growth by mea-
suring absorbance at 600 nm (OD600).
o When the OD600 reaches 0.8, take a 1ml aliquot as the “non-in-
duced” sample (centrifuge and keep on ice), and then induce the
culture with 1mM (final concentration) of IPTG.
o Shake at 30 °C at 200 rpm for 4 h.
o Take a 1ml aliquot as the “induced” sample.
o Aliquot the culture into 50ml falcon tubes (or other appropriate
vessels) and centrifuge at 4,500 rpm for 10min to pellet bacteria.
Also pellet the “non-induced” and “induced” samples by cen-
trifugation.
o Remove the supernatant and snap-freeze the pellets in liquid ni-
trogen. Store at −80 °C.
• Day 4:
o Defrost the pellets from the 300ml culture (usually 6×50ml
falcon tubes) quickly at room temperature then transfer to ice.
o To each falcon tube (pellet derived from 50ml culture), add 15ml
of cold PBSA containing protease inhibitors and resuspend the
pellet completely by careful pipetting, or vortexing. Avoid dena-
turing proteins, often signified by bubbles in the mixture.
Combine all 6 samples (90ml total) into one 200ml glass beaker.
o Sonicate with a tip probe sonicator (Branson Digital Sonifier 250)
at 33% output, with 15 s ON, 30 s OFF pulses, for a total ON pulse
duration of 10min. Keep the sample on ice at all times. If a dif-
ferent sonicator is used, the conditions for cell lysis will have to be
optimised.
o Add Triton-X100 to a final concentration of 0.5%, mix gently.
o Incubate on ice for 30min.
o Transfer the sonicated lysates to appropriate vessels and cen-
trifuge at 12,000 rpm for 10min at 4 °C to remove debris.
Alternatively, 4,500 rpm for 30min in falcon tubes can be used.
o Transfer the supernatant to new 50ml falcon tubes on ice (dis-
tribute 90ml of cleared lysate as 3×30ml aliquots). Also take a
1ml aliquot as the “lysate” sample. Successful expression of the
GST-Dsk2 protein may be tested by gel electrophoresis and
staining with Coomassie Blue before proceeding.
o Resuspend the glutathione sepharose beads well and take 3ml of
suspension into a fresh tube (this corresponds to 1.5 ml packed
bead volume). Spin at 500 g for 5min at 4 °C and remove super-
natant carefully. Wash once with cold PBSA, and then resuspend
in 3.3 ml cold PBSA.
o For binding of GST-Dsk2 to the beads, add 1ml of well-re-
suspended glutathione sepharose bead solution from the previous
step to each 30ml of cleared lysate. Also add DTT to a final
concentration of 2mM. Rotate gently in the cold room for at least
4 h or overnight.
• Day 5:
o Spin binding reactions at 500 g for 5min at 4 °C. Remove and save
the supernatant as the unbound fraction.
o Wash the beads twice with ice-cold PBSA, 0.1% Triton X-100,
containing protease inhibitors. During one of the washes, combine
the pellets from the 3 falcon tubes into one.
o Wash once more with PBSA without Triton X-100, but containing
protease inhibitors.
o Add 30ml of PBSA containing protease inhibitors and 0.02% so-
dium azide to the prepared Dsk2 beads and store at 4 °C. In our
hands, the beads can be stored for long periods of time (months)
without losing efficiency.
• Day 6:
o To check the efficiency of the Dsk2 bead preparation, pipet 100 μl
of “non-induced”, 100 μl of “induced” and 100 μl of “lysate” into
Eppendorf tubes. Also pipet 250 μl of prepared Dsk2 bead sus-
pension (12.5 μl packed beads) into a tube, spin at 500 g for 5min
at 4 °C, and remove the supernatant. Add a corresponding amount
of Laemmli buffer containing DTT or β-mercaptoethanol to each
sample including the pelleted Dsk2 beads, and boil at 96–98 °C for
5min. Spin at max speed for 5min to remove debris or beads.
Transfer supernatants to new tubes.
o Run the samples on a polyacrylamide gel (typically 4–15%) and
stain the gel with Coomassie or similar. GST-Dsk2 protein should
run at ∼65 kDa, and some free GST band may also sometimes be
seen at ∼28 kDa.
3.4. Preparation of MultiDsk affinity resin
MultiDsk plasmid (pGST-MD) is propagated and MultiDsk protein
expressed as described for GST-Dsk2 in Section 3.3 up to day 4, with the
exception that IPTG is added when the OD600 reaches 0.6. Since the
MultiDsk protein is found in inclusion bodies, we use a different method
of lysis and purification as described below.
• Day 4:
o Defrost the pellet from the 300ml culture quickly at room tem-
perature then transfer to ice. Add 20 pellet volumes of STE buffer
(10mM Tris pH 8.0, 100mM NaCl, 1 mM EDTA, protease in-
hibitors) containing lysozyme at 0.1 mg/ml and resuspend the
pellet completely by careful pipetting, or vortexing. After 15min
on ice, add sarcosyl (N-lauryl sarcosine) to a final concentration of
1.5% in order to denature the protein.
o Sonicate with a tip probe sonicator (Branson Digital Sonifier 250)
at 20% output, with 15 s ON, 30 s OFF pulses, for 4 cycles. Keep
the sample on ice at all times. If a different sonicator is used, the
conditions for cell lysis will have to be optimised.
o Centrifuge at 10,000 g for 5min to remove insoluble material.
Save the supernatant and take an aliquot for analysis.
o Add Triton X-100 to the supernatant at a final concentration of
3%. Triton X-100 masks the sarcosyl by forming mixed micelles
allowing the protein to refold.
o Add this lysate to glutathione beads, pre-equilibrated in STE
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buffer. Use approximately 1ml resin per 1ml bacterial pellet
starting material. Add DTT to 2mM. Rotate gently in the cold
room for at least 4 h or overnight.
• Day 5:
o Spin bead-binding reactions at 500 g for 5min at 4 °C. Remove
and save the supernatant as the unbound fraction.
o Wash the beads twice with ice-cold STE containing 500mM NaCl
and 0.1% Triton X-100, followed by a wash in the same buffer at
50mM NaCl.
o Wash twice with PBSA. Then add 30ml PBSA.
o The beads can be stored in PBSA, 0.02% sodium azide at 4 °C. In
our hands, the beads can be stored for long periods of time
(months) without losing efficiency.
• Day 6:
o Check the efficiency of MultiDsk bead preparation, as for Dsk2
beads. GST-MultiDsk protein should run at ∼60 kDa, and some
free GST band may also sometimes be seen at ∼28 kDa.
3.5. Generating cell lysates from human and yeast cells
3.5.1. Human whole cell lysates
• Seed at least one 10 cm dish per condition. Apply treatments as
required for your model system (e.g. siRNA, UV-irradiation, drug
treatment, etc). At the time of collection, the cells should ideally be
60–80% confluent.
• Note: it is not necessary to use proteasomal inhibitors to observe
RPB1 poly-ubiquitylation in human cells, if the optimal experi-
mental timepoints are chosen (see Section 3.8).
• Aspirate the media and add the appropriate amount of PBS (e.g.
1–2ml for a 10 cm or 15 cm dish).
• Immediately scrape cells off and transfer to a tube.
• Spin at 1300 rpm for 3min, remove supernatant. The pellets can be
flash-frozen in liquid nitrogen at this point and stored at −80 °C.
• Add the appropriate volume of TENT buffer (50mM Tris-HCl pH
7.4, 2 mM EDTA, 150mM NaCl, 1% Triton X-100) containing pro-
tease inhibitors, phosphatase inhibitors and 2mM of N-ethylmalei-
mide [NEM; a potent and inexpensive cysteine protease (e.g. DUB)
inhibitor] to the pellet. We typically use 1ml of TENT buffer for a
pellet from a 10–15 cm dish. Note that the NEM stock solution
(200mM in ethanol) should be made up fresh every time.
• Leave on ice for 10min.
• Sonicate in a 4 °C water bath sonicator (Bioruptor) at high power,
with 30 s ON and 30 s OFF pulses, for a total duration of 7min, or by
using a single sonication pulse (10 s at 20% output) with the tip-
probe sonicator (Branson). Alternative sonicators can be used but
the conditions would need to be optimised.
• Transfer to Eppendorf tubes and centrifuge at maximum speed
(14,000 rpm) for 5min to remove debris.
• Transfer the supernatant (lysate) to a new tube. Quantify the protein
concentration using a Bradford assay or similar.
3.5.2. Yeast whole cell lysates
• Harvest approximately 3×108 yeast cells by centrifugation. At the
time of collection, the cells should ideally be in early log phase
(5×106–2×107 cells/ml).
• Note: MG132 is not added to yeast cell media as yeast cells are
impermeable to it, but it is used later in the lysis buffer to prevent
protein degradation in the lysates (see below).
• Wash once in PBS before flash-freezing the pellets in liquid nitrogen.
• Thaw pellets and resuspend in 800 μl buffer (150mM Tris-acetate
pH 7.4,100mM potassium acetate, 1 mM EDTA, 0.1% Triton X-100,
10% glycerol, 2 mM NEM, 10 μM MG132 and protease inhibitors).
• Add roughly 500 μl 0.5 mm diameter glass beads (BioSpec Products)
and disrupt the cells using a FastPrep-24 cell homogenizer (MP
Biosystems), using 6 rounds of beating at an intensity of 5.5, for 30 s
each. Incubate samples on ice for 1min between disruptions, to
reduce heating of the sample with an additional 5-minute ice in-
cubation after 3 rounds. If a different method of homogenization is
used, the conditions for cell lysis will have to be optimised.
• Clarify the extracts at 20,000 g for 10min. Save supernatant and
repeat centrifugation until the lysate is clear.
• Determine the protein concentrations of the extracts using the Bio-
Rad protein assay or similar.
3.6. Enrichment of ubiquitylated proteins using Dsk2 beads
3.6.1. Dsk2 pulldown with human cell lysates:
• Day 1:
o We typically use 0.5 ml of GST-Dsk2 (or MultiDsk) bead suspen-
sion (equivalent to 25 μl packed beads) prepared as described in
Section 3.3, to deplete/enrich ubiquitylated proteins from 1mg of
whole cell protein extract.
o Keep both beads and protein samples on ice at all times.
o For each cell lysate sample, pipet 1mg of total protein into 2ml
safe-lock Eppendorf tube and slowly adjust all samples to the same
volume with TENT buffer containing protease inhibitors, phos-
phatase inhibitors and 2mM freshly made NEM. Typically, the
final sample volume should be between 700 μl and 1ml.
o Note: it is possible to use less than 1mg of protein per pulldown –
we have tested amounts down to 300 μg. In this case, the volume
of Dsk2 beads and the total reaction volume should be scaled
accordingly.
o Prewash the beads in bulk. Spin beads at 500 g for 5min at 4 °C,
remove supernatant and wash once with TENT buffer containing
protease inhibitors, phosphatase inhibitors and 2mM NEM (see
Section 3.5.1).
o Note: sepharose beads are very easily disturbed when removing
the supernatant. It is therefore better to leave some supernatant
behind than to accidentally remove some of the beads from the
pellet.
o Gently resuspend beads in a smaller volume of TENT buffer con-
taining protease inhibitors, phosphatase inhibitors and 2mM
NEM (typically 220 μl per sample). Avoid making bubbles.
o Aliquot the same volume (typically 200 μl) of well-resuspended
Dsk2 bead slurry to each sample.
o Rotate on a turning wheel/rotator (low to moderate speed) in the
cold room for several hours to overnight.
• Day 2:
o Spin the samples at 500 g for 5min at 4 °C, remove supernatant
and save as “unbound” fraction. Wash the beads carefully twice
with 1ml of TENT buffer containing protease inhibitors, phos-
phatase inhibitors and 2mM NEM.
o Wash the beads carefully once with 1ml of PBS containing pro-
tease inhibitors, phosphatase inhibitors and 2mM NEM. Spin at
500 g for 5min at 4 °C and remove as much supernatant as pos-
sible. Re-spin a few times if necessary. At this point, any re-
maining liquid may also be removed with a fine pipet-tip.
o To each bead sample, add 40 μl of Laemmli buffer containing DTT
or β-mercaptoethanol, mix by brief vortexing, and boil at
96–98 °C for 5min.
o Spin the samples and save supernatant which now contains the
enriched, ubiquitylated proteins (“bound” fraction). Samples can
be run on SDS gels at this point or can be frozen.
o Note: it is possible to elute bound proteins from the Dsk2/
MultiDsk beads by the addition of 50mM Phosphate buffer pH
8.1, 300mM KCl, 10% glycerol, 1xPIs, 0.05% Triton X-100,
15mM Glutathione, pH adjusted to>8.1 [38]. This is only re-
quired if the bound fraction is to be used for analysis other than
WB (e.g. mass spectrometry or further binding assays).
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o Note: “unbound” and “bound” fractions can be run on the same
gel, and a Western blot with anti-ubiquitin antibodies can be used
to determine the efficiency of the pulldown (e.g. see [38]). In our
hands, with the conditions outlined here (and overnight incuba-
tion for binding to beads), an apparently near-complete depletion
of poly-ubiquitylated proteins from human extracts can be
achieved. Using more than 0.5 ml of Dsk2 bead suspension (25 μl
packed beads) per reaction does not yield markedly better en-
richment of ubiquitylated proteins. However, the experimenter is
advised to check the efficiency of their own Dsk2 bead prepara-
tion to determine optimal bead-to-sample ratios.
3.6.2. Dsk2 pulldown with yeast cell lysates:
Dsk2 pulldowns from yeast extracts are carried out as with mam-
malian cell extracts, except for the following points:
• Typically, Dsk2 pulldowns with yeast extracts are performed with
2mg of extract in a total volume of 1ml and 30 µl of packed affinity
resin. Adjust volumes with lysis buffer containing protease in-
hibitors, NEM and MG132.
• The extract and resin are incubated at 4 °C for two hours only;
overnight incubations result in degradation of the Dsk2 protein.
• The resin should be washed once in the extract buffer, followed by
two washes in the extract buffer with 300mM potassium acetate,
before a final wash in extract buffer.
• Elution should be performed as for mammalian cells.
3.7. Western blot analysis of Dsk2- and MultiDsk- enriched fractions
• The input and Dsk2/MultiDsk-enriched samples should be gel-ana-
lysed with enough spacing between them – we recommend running
the input and Dsk2-enriched samples on different sides of the gel as
the signal will often be much stronger in the inputs. We routinely
use ∼5 μg of human cell lysate as input and 10–20 μl of the “Dsk2-
bound” fraction (see previous section).
• To resolve Dsk2-enriched, ubiquitylated RPB1, we typically use a
3–8% Tris-Acetate gel, and continue electrophoresis until the
75–100 kDa marker runs out. Alternatively, 4–15% TGX gels can be
used, again until the 75–100 kDa marker runs out.
• We use wet protein transfer (500mA for 1 h), in a transfer buffer
without SDS or alcohols, and nitrocellulose membranes with
0.45 μm pores. Other transfer conditions may be suitable but have to
be optimised by the experimenter.
• Upon transfer, membranes should be stained with Ponceau S and
image-scanned for future reference. To block membranes, incubate
in PBS+0.05% Tween (PBST) with 5% skimmed milk powder for
1 h at room temperature.
• Note: 4H8 is the most commonly used primary antibody for detec-
tion of ubiquitylated RPB1, as it recognises most forms of RPB1 (but
preferentially the phosphorylated form) with high affinity (4H8 is
available from a number of commercial providers). Other RBP1
antibodies can be used as well, but they will generally give lower
signal intensity. In addition to RPB1, a housekeeping protein such as
human Vinculin (∼120 kDa), or yeast Tub1 (50 kDa) or Pgk1
(45 kDa) should be probed against as well to control for loading in
the inputs.
• From this step, standard Western blot procedures should be applied.
For 4H8, we use a 1:10,000 primary antibody dilution (stock con-
centration 1mg/ml).
3.8. Considerations for Dsk2/MultiDsk pulldown assay
• Timing – when to look for RNAPII ubiquitylation after a stimulus? In the
case of UV-irradiation, RPB1 poly-ubiquitylation can be detected as
early as 10min after irradiation. The poly-ubiquitylated smear
peaks around 30min after UV, and is present up to a few hours after
UV-irradiation (Fig. 2B), in both mammalian and yeast cells. As
RPB1 molecules are getting ubiquitylated, they will also start to be
degraded (see next section). The decrease in poly-ubiquitylated
smears that is observed at time-points after ∼60min can be at-
tributed to a decrease in transcription (only elongating RNAPIIs
stopped by DNA lesions are ubiquitylated and degraded) [12] and to
a reduction in overall RPB1 levels in the cell, rather than to a loss of
ubiquitylation activity (Fig. 2B).
The dynamics of RPB1 poly-ubiquitylation described above applies
to wild type cells, but various perturbations such as gene knock-
outs, knock-downs, or mutations may affect this behaviour. For
example, depletion of the E3 ubiquitin ligase NEDD4 affects RPB1
poly-ubiquitylation in early stages of the UV-response (10–20min)
whereas at later timepoints after UV, little or no change is observed
between NEDD4-depleted and wild type cells [12]. We therefore
recommend that the pilot experiments always include multiple
timepoints, spanning both early (10–30min) and late timepoints (a
few hours) after a perturbation.
• Use of proteasome inhibitors. If optimal timepoints are chosen (see
previous point), the use of proteasome inhibitors such as MG132 is
not required to observe human RPB1 poly-ubiquitylation. However,
proteasome inhibitors can of course be used, if the experimental
question requires so (for example to confirm that disappearance of
the smear at later timepoints was indeed due to proteasomal de-
gradation of the poly-ubiquitylated RPB1 species). In this case, we
typically use a 1–3 h pre-incubation with 5 μM MG132. It is im-
portant not to add a very concentrated MG132 stock solution di-
rectly to cell culture media as precipitates will form – we typically
dilute the original 50mM MG132 stock (in DMSO) 1:500 (in warm
media) and add the diluted stock to cells. In yeast, MG132 is used
only in the protein extraction buffer.
• Pulldown efficiency. When performing a Dsk2/MultiDsk pulldown,
especially for the first time, it is recommended to run the input,
unbound and bound fractions on protein gels and probe with an
anti-ubiquitin antibody. This will show whether similar amount of
input material was used, and reveal how efficient the pulldown is
under the given conditions. The amount of beads and lysate can be
varied to find optimal pulldown conditions (e.g. see [38]).
• Replicates. Even though Dsk2/MultiDsk pulldown is highly efficient,
it suffers from some technical variability as any other method. We
therefore recommend running each experiment as three in-
dependent, biological replicates. This becomes particularly im-
portant if one expects only moderate differences in RPB1 poly-ubi-
quitylation between different samples.
• Alternative uses. Dsk2/MultiDsk pulldown can be coupled with ap-
plications other than Western blot, such as mass spectrometry to
identify ubiquitylated proteins proteome-wide, or further purifica-
tions (see below). Upon pulldown, bound proteins together with
Dsk2/MultiDsk itself can be eluted with glutathione [38]. Alter-
natively, Dsk2/MultiDsk can be chemically crosslinked to the se-
pharose beads prior to pulldown, and upon pulldown, the bound
proteins (without Dsk2/MultiDsk) can be eluted, for example by
boiling in Laemmli buffer.
3.9. Troubleshooting Dsk2/MultiDsk pulldown assay
• No signal in the pulldown fractions or variable signal between pulldown
samples where it is not expected due to biology. Possible reasons:
o Low pulldown efficiency – was the efficiency checked with anti-
ubiquitin antibody?
o Antibody not working in Western blot – is the expected band(s)
detected in the input samples?
o Deubiquitylation of proteins in the extract – has freshly-made
NEM been added to lysis buffer and pulldown reactions?
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4. Tracking RNAPII degradation
Background: RPB1 degradation can be assessed by Western blot
analysis, with some specific considerations outlined below.
4.1. Method: analysing RNAP II degradation by Western blot
Either whole cell extracts or chromatin fractions can be used to
assess RPB1 degradation in mammalian cells. Most extraction protocols
will be suitable as long as protease inhibitors, phosphatase inhibitors
and freshly made NEM are added.
For yeast cells, the protocol for preparing lysates for Dsk2-pulldown
can be used. Alternatively, it may be preferable to use a quicker lysis
method that requires significantly less cells, such as alkaline quick
whole cell extract preparation [40]. Briefly, 1–2×107 cells are pelleted
and resuspended in 100 μl of 100mM NaOH for 5min at room tem-
perature. Cells are pelleted and the pellet resuspended directly in 50 μl
of 1.5X Laemmli loading buffer and boiled for 5min, before placing on
ice. Samples are re-heated and spun at 14,000 g for 1min before
loading on SDS-PAGE gels (for measuring Rpb1 degradation, we usually
load 8 μl per sample). Using this method, it is not possible to measure
the protein concentration and so it is important to ensure that an equal
number of cells is processed per condition, and to employ a non-de-
graded control protein.
To perform the Western blot:
• 10–50 μg of total protein should be loaded. It is important that equal
amounts of protein are added to compare the different samples.
• To resolve unphosphorylated and phosphorylated RPB1, 3–8% Tris-
Acetate gels should be used, and electrophoresis continued until the
75–100 kDa marker position runs out. Alternatively, 4–15% TGX
gels can also be used as long as the 75–100 kDa marker protein runs
out of the gel.
• We use wet protein transfer (500mA for 1 h), transfer buffer without
SDS or alcohols, and nitrocellulose membranes with 0.45 μm pores.
Other transfer conditions may be suitable but have to be tested by
the experimenter.
• Upon transfer, membranes should be stained with Ponceau S and
scanned for future reference. To block membranes, incubate in
PBS+0.05% Tween (PBST) with 5% skimmed milk powder for 1 h
at room temperature.
• From this step, standard Western blot procedures should be applied.
• The choice of antibody for detecting RPB1 degradation is very im-
portant. We recommend using phospho-unbiased antibodies, such as
those raised against RPB1 N-terminus (N-20, D8L4Y, ARNA-3),
when analysing RPB1 degradation. This is because stimuli such as
UV-irradiation can cause RPB1 phosphorylation changes as well as
degradation. Thus, interpreting changes of abundance of only the
phosphorylated forms of RPB1 might be difficult. (Fig. 3A, also see
“Considerations” below).
• Important note: Antibodies raised against the N-terminal of human
RPB1 will not recognise yeast Rpb1. Unlike human RPB1, yeast
Rpb1 migrates as a single band on polyacrylamide gels. To assess
yeast Rpb1 degradation, 4H8 antibody can be used. Alternatively,
yeast strains with tagged, endogenous Rpb1 can be generated, with
anti-tag antibodies used to analyse Rpb1 degradation. We have
successfully used this technique with a standard 3×HA C-terminal
tag on Rpb1 which was generated by homologous recombination
[41].
4.2. Considerations
• Timing – when to look for RNAP II degradation after a stimulus? The
extent of RPB1 degradation will depend on the intensity of the sti-
mulus – in the case of UV, the dose of irradiation. Doses between 10
and 20 J/m2 will induce almost complete degradation of RPB1 in
HEK293 cells around 3–6 h after UVC-irradiation. Lower doses of UV
will have similar dynamics but will cause degradation of a smaller
percentage of RPB1 molecules (Fig. 3B). The amount of RPB1 will
typically recover to original levels around 24–48 h after UV-irra-
diation (Fig. 3B). To observe UV-induced Rpb1 degradation in yeast,
hourly time points are typically taken for 4 h. In contrast, when
using 4-NQO in yeast, the time course is typically every 30min for
120min total (this time-course is appropriate for 10 μg/ml 4-NQO;
for other concentrations the time course will need to be optimized).
• Coinciding RPB1 phosphorylation changes – Upon UV-irradiation of
human cells, a characteristic RPB1 “hyperphosphorylation” can be
observed, involving an almost complete shift of the unpho-
sphorylated IIa band to the hyper-phosphorylated state (IIo).
Importantly, two opposing forces will affect the total amount of
phosphorylated RPB1 (IIo form) observed: continued CTD phos-
phorylation will increase its levels, while degradation will decrease
it. Using phosphorylation-independent antibodies, such as N-20,
D8L4Y or ARNA-3, raised against RPB1 N-terminus, will therefore
provide an objective image of total RPB1 levels, influenced by de-
gradation (Fig. 3A). As noted before, to assess Rpb1 degradation in
yeast, either tagged-Rpb1 or 4H8 antibody can be used.
• Using proteasome inhibitors – Overall levels of a protein are de-
termined by its synthesis rate and its destruction rate. In order to
verify that the depletion of RPB1 is truly caused by proteasomal
UV:
- + - +
MG-132 (5ȝM): - +
RPB1
(D8L4Y)
Vinculin
IIo
IIa
RPB1
(D8L4Y)
long expo.
250 kDa
250 kDa
100 kDa
IIo
IIa
UV (J/m2): -
Recovery time:
5 10 20
3h
5 10 20
24h
5 10 20
48h
RPB1
(D8L4Y)
IIo
IIa
Vinculin
250 kDa
100 kDa
UV:
(3h, 20 J/m2)
- + - +
- + - +
IIo
IIa250 kDa
100 kDa
Vinculin
RPB1 antibody:
D8L4Y
(total)
4H8
(all forms)
3E8
(S5-P)
3E10
(S2-P)
A
B
C
Fig. 3. Analysis of RNAPII degradation. (A) Comparison of different RPB1 an-
tibodies for detection of UV-induced RPB1 degradation. Identical samples (ly-
sates from HEK293 TRex flpIn cells, either untreated or irradiated with 20 J/m2
UVC and collected 3 h post-irradiation), were run in quadruplicate on the same
gel, and the membrane was cut and probed with different antibodies, re-
cognising either total RPB1 (D8L4Y), all forms of RPB1 (with preference for the
phosphorylated form) (4H8), Ser 5-phosphorylated RPB1 (3E8), or Ser 2-
phosphorylated RPB1 (3E10). (B) Dose-dependent RPB1 degradation upon UV
irradiation. HEK293 TRex flpIn cells were irradiated with 5, 10 or 20 J/m2
UVC, and samples were taken at different timepoints after irradiation. (C) Use
of the proteasome inhibitor MG132 to confirm proteasomal degradation of
RPB1. HEK293 TRex flpIn cells were pre-treated with 5 μM MG132 for 3 h, UV
irradiated with 20 J/m2 UVC, and samples were collected 3 h after irradiation.
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degradation, MG132 or another proteasome inhibitor can be used
(Fig. 3C). In human cells, we typically use 5–10 μMMG132, added a
few hours before UV treatment. In yeast, MG132 is used only in the
lysis buffer. Wild type yeast are not sensitive to MG132 as it cannot
efficiently enter the cells [42]. Mutant strains and chemical strate-
gies have been described that increase the uptake of MG132 [43,44]
leading to accumulation of high molecular weight ubiquitin con-
jugates upon MG132 treatment [26]. However, these methods are
not suitable for analysis of Rpb1 ubiquitylation and degradation
because MG132 blocks proteasome-mediated Def1 processing, a
critical pathway that is required for Rpb1 poly-ubiquitylation and
degradation [26].
• Using protein synthesis inhibitors – In human cells, UV-induced RPB1
degradation can be observed even without using the protein
synthesis inhibitor cycloheximide, showing that degradation of
RPB1 is more rapid than synthesis of new RPB1 molecules. Indeed,
without cycloheximide, human cells recover RPB1 levels only
24–48 h after a medium to strong dose of UV-irradiation. In contrast,
yeast cells are capable of recovering Rpb1 levels much faster than
human cells – a few hours after UV. Depending on the strain back-
ground, this can often make it difficult to capture the correct
timepoint(s) to detect Rpb1 degradation. Addition of cycloheximide
(25 μg/ml) to yeast cells immediately before UV treatment largely
alleviates this problem. We have successfully observed Rpb1 de-
gradation both in the absence [9] and presence [26] of cyclohex-
imide and it is important to be aware that the profiles will look
different depending on which method is chosen.
• Replicates – As with any experiment, we recommend performing the
analysis in at least three independent, biological replicates. If ex-
pected/observed differences between the samples are moderate,
image analysis (using programs such as ImageJ) can be used to
quantify these differences. Loading controls such as Vinculin
(human cells), and Tub1 or Pgk1 (yeast) can be used to normalise
the data.
4.3. Troubleshooting RPB1 degradation analysis
• No RPB1 degradation in samples where it is expected. Possible reasons:
o Unequal loading. Ensure that equal amounts are loaded based on
the control protein.
o Insufficient dose of the stimulus – try increasing the dose of the
stimulus (see Table 1) and test different timepoints, and – if using
UV-irradiation- check that the UV-irradiator and UV meter are
working correctly.
o Old reagents – some agents, such as cisplatin, need to be made
fresh every time, otherwise they are hydrolysed or lose activity in
solution.
o For both of the above, it is useful to also blot for markers of the
given stimulus (e.g. DNA damage markers such as γH2AX for
cisplatin or UV) to check that the treatment has worked.
• Additional bands or background in Western blot apart from IIo and IIa.
Possible reasons:
o Non-specific degradation of proteins – have protease inhibitors
been added to the lysis buffer? Has the sample been kept cold at
all times? Have the samples been boiled in Laemmli buffer for too
long (more than 7–8min)?
o Primary/secondary antibody background – try using different
antibodies.
• Phosphorylated RPB1 band (IIo) appears too weak. Possible reasons:
o Non-specific dephosphorylation of proteins – has phosphatase
inhibitor been added to the lysis buffer?
5. Outlook – investigating specific ubiquitylation sites on RNAPII
5.1. Mapping individual ubiquitylation sites on RNAPII
Apart from targeting proteins for degradation, ubiquitylation can
also act as a signalling module, in the form of mono-ubiquitylation or
ubiquitin chains with linkage other than K48 [45]. It is thus possible
that RNAPII is marked with several, different kinds of ubiquitylation.
The functional importance of different ubiquitylation sites on RNAPII is
typically not known.
While it is possible to couple Dsk2/MultiDsk pulldown with mass
spectrometry, if Dsk2/MultiDsk are first crosslinked to the beads (see
Section 3.8), this approach will typically only identify ubiquitylated
proteins, but not necessarily the exact sites of ubiquitylation on each
target protein. To map individual sites of ubiquitylation, enrichment of
peptides with a Ubiquitin Branch Motif (K-ε-GG) antibody can be used.
This principle is often referred to as diGly immunoprecipitation (diGly
IP) [46], and can be coupled to stable isotope labelling with amino
acids in cell culture (SILAC) labelling to enable quantitative profiling of
ubiquitylation sites proteome-wide (see, for example, [33,47,48]). It is
important to note that the diGly antibody enriches for three types of
post-translational modifications indiscriminately: ubiquitylation, ned-
dylation and ISGylation. However, given the abundance of the three in
the cell it is fair to assume that most diGly peptides stem from a ubi-
quitylation event.
Building on the above, we have established a few modifications to
this procedure in human cells. Briefly, we employed a SILAC-based
quantitative proteomics approach. Cells are grown in media containing
heavy- or light-isotope-containing amino acids to achieve light/heavy
labelling of proteins [49].
Cells are then pelleted and lysed by addition of 9 cell-pellet volumes
of 9M urea solution (9M urea in 20mM Hepes pH 8.0) and sonicated to
facilitate extraction of chromatin-bound proteins. Optionally, 100 U/ml
of benzonase may be added to the lysate prior to sonication to facilitate
the process. Lysates are then cleared by centrifugation, and equal
amounts of protein from each sample (typically 30mg) is subjected to
LysC and tryptic digests, as specified by the Ubiquitin Remnant Motif
(K-ε-GG) Kit manufacturer. After C18-reverse phase purification using
Sep Pak cartridges, ubiquitylated peptides are enriched using K-ε-GG
antibody conjugated to protein A agarose beads. 40 μl of antibody-
coupled beads are used per 30mg of input sample. Enriched peptides
are eluted with 0.15% TFA, lyophilized, and subjected to SCX (strong
cationic exchange) or basic reverse phase fractionation [33,48,50]. The
fractions are then analysed using LC MS/MS in combination of nanoLC
and a suitable mass spectrometer (e.g. LTQ-Orbitrap Velos Q-Exactive
Orbitrap or an Orbitrap Fusion Lumos) [48,50,51]. This approach
should typically yield between 5000 and 10,000 ubiquitylation sites per
experiment. Using this method, multiple UV-induced ubiquitylation
sites can be identified on RNAPII [33,47,48]. Additionally, for analysis
of a larger number of different conditions, the diGly enrichment prin-
ciple can be coupled with multiplexing procedures such as Tandem
Mass Tag (TMT) Systems [51] instead of SILAC labelling.
For the diGly IP protocol in yeast cells please refer to a study by
Espenshade and colleagues [52]. In this study diGly IP has been per-
formed on previously enriched ubiquitylated proteins, isolated from
yeast cells expressing His-tagged ubiquitin using nickel affinity pur-
ification. Therefore, it might be possible to apply the same principle in
yeast or human cells using Dsk2/MultiDsk enrichment of ubiquitylated
proteins and subsequent diGly IP, which might result in an even better
detection of ubiquitylation sites than using diGly IP alone.
We envisage that mapping individual sites of ubiquitylation on
RNAPII using methods outlined above will be crucial for understanding
the molecular mechanisms that mediate RNAPII degradation under
different conditions.
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5.2. Model systems to study RNAPII PTMs, including ubiquitylation
The RNAPII complex harbours numerous post-translational mod-
ifications (PTMs), the most famous being CTD phosphorylation. These
modifications are a platform for regulating RNAPII behaviour at dif-
ferent stages of transcription. Even for the most well studied RNAPII
PTMs, such as phosphorylation of Serine 5 or Serine 2 within the CTD
hepta-peptad repeats, novel roles are constantly emerging (see, for
example, [53]). This only highlights how much is still unknown,
especially regarding other, more difficult-to-study RNAPII modifica-
tions such as ubiquitylation.
When studying PTMs, the first approach is often to mutate the
modification acceptor site on the target protein. To prevent ubiquity-
lation of a specific lysine residue, lysine (K) is mutated to either the
conservative arginine (R) or, less optimally, to alanine (A). While K→
R/K→A mutant proteins can be tagged, overexpressed and purified for
in vitro assays, the challenge remains of how to study the functions of a
particular mammalian PTM in vivo. To elucidate the roles of a PTM in
vivo, the endogenous wild type protein has to be replaced with the
mutated version. For human RNAPII, the most commonly used model
system to achieve this is the α-amanitin resistance system [54,55]. α-
amanitin is a mushroom amatoxin that binds the catalytic site of
RNAPII. This blocks its forward translocation [56] and induces rapid
RPB1 degradation [57]. A specific mutation in RPB1 has been identified
(N793D) that confers resistance to α-amanitin [58]. This mutation has
been exploited to generate α-amanitin-resistant RPB1 constructs that
also harbour CTD deletions, or desired mutations in PTM sites, for ex-
ample [54,55,59]. By transiently transfecting these constructs into cells,
and treating with α-amanitin, the “switchover” from endogenous (‘α-
amanitin-degraded’) to the mutated, α-amanitin-resistant RNAPII is
achieved. This and other systems like it can be used to investigate the
short-term effect of often lethal mutations in the RPB1 (POLR2A) gene.
For studying long-term effects of a given RNAPII PTM, alternative
“switchover” systems may be developed by targeting the endogenous
RNAPII loci with siRNA/shRNA or CRISPR-mediated knock-outs, while
at the same time expressing PTM-mutant forms from stably integrated
sites in the genome. Finally, it may be possible to target the endogenous
RNAPII loci with CRISPR-mediated knock-in point mutations in the
desired PTM sites when these mutations are not lethal.
6. Conclusions
Affinity resins based on ubiquitin binding domains such as Dsk2 or
MultiDsk provide a robust and easy method to enrich endogenous
ubiquitylated proteins in their native state. Importantly, these strategies
are suitable not only for analysis of RNAPII ubiquitylation, but also of
any other ubiquitylated protein, and can be coupled either to Western
blot or other analyses, such as further purification or mass spectro-
metry. While Dsk2 protein alone has some preference towards K48-
linked ubiquitin chains, MultiDsk binds different kinds of ubiquitin
chains equally well. Nonetheless, both resins successfully enrich poly-
ubiquitylated RNAPII species, although Dsk2 resin is preferable for this
purpose as it does not enrich the mono-ubiquitylated form to an extent
where it affects the visualization of the often weaker RPB1 poly-ubi-
quitylation signal.
RNAPII ubiquitylation triggered by transcription stress, such as that
caused by bulky DNA lesions, targets RNAPII for degradation by the
proteasome. The kinetics and peak time of RNAPII degradation will
depend on the type and intensity of the stress stimulus (DNA damage,
NTP depletion, RNAPII inhibitors). Some of these agents also induce
changes in RNAPII phosphorylation patterns, thus using the phos-
phorylation-unbiased antibodies for detection of total RNAPII levels is
recommended.
At present, it is unclear which exact sites on RPB1 are modified by
ubiquitylation, and by what type of ubiquitin chains, and how such
modification affects RNAPII function. As multiple E3 ubiquitin ligase
pathways have been implicated in targeting RNAPII, this question be-
comes increasingly important. Advanced strategies for profiling in-
dividual ubiquitylation sites in the proteome and generating suitable
model systems to study those, will be crucial to understand how the
“ubiquitin code” regulates the behaviour and fate of RNAPII.
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Appendix
Equipment and supplier list
UV source Stratalinker or similar Stratagene
UV radiometer VLX-3W 513000111 Progen Scientific
UV Sensor SX-254 Radiometer Sensor 254 nm 549000011 Progen Scientific
Bulbs Stratalink 2400 Bulbs, 365 nm 254 nm 400079 Agilent
α-amanitin sc-202440A Santa Cruz
6-azauracil (6-AU) A1757 Sigma
Cisplatin P4394 Sigma
N-Ethylmaleimide (NEM) 04260 Sigma
MG132 10012628 Cambridge Bioscience
4-Nitroquinoline N-oxide (4-NQO) N8141 Sigma
Glutathione Sepharose Beads GE17-0756-01 Sigma
cOmplete(TM), EDTA-free Protease Inhibitor Cocktail 5056489001 Sigma
Antibodies
RPB1 (4H8) ab5408 Abcam (or similar)
Rpb1 NTD (D8L4Y) 14958S NEB
RPB1 P-Ser2 (3E10) 04-1571 Merck Millipore
RPB1 P-Ser5 (3E8) 04-1572-I Merck Millipore
α-Pgk1 459250 Invitrogen
Tubulin (TAT-1) 00020911 Sigma
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Vinculin V9131 Sigma
K-ε-GG (PTMScan kit) 5562 Cell Signaling Technology
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.ymeth.2019.02.005.
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